Background. Adrenocortical carcinoma (ACC) is a rare but lethal tumor. Predictors of survival include earlier stage at presentation and complete operative resection. We assessed effect of treatment and demographic variables on survival. Methods. ACC cases were abstracted from the California Cancer Registry and Office of Statewide Health Planning and Development (1999-2008). Predictors included patient demographics, comorbidities, tumor size, stage, and treatment (none, surgery, chemotherapy and/or radiation [CRT], and surgery plus CRT). Results. We studied 367 patients with median tumor size of 10 cm. At presentation, 37% had localized, 17% had regional, and 46% had metastatic disease. Median survival was 1.7 years (7.4 years local, 2.6 years regional, and 0.3 years metastatic, P < .0001). One-year and 5-year survival was: 92%/62% (local); 73%/39% (regional); and 24%/7% (metastatic). Increased age (hazard ratio [HR] 1.16) and Cushing's syndrome (HR 1.66) worsened survival (P < .05). Low socioeconomic status worsened survival in local and regional disease (P < .05). In multivariable regression, both surgery (regional HR 0.13; metastatic HR 0.52) and surgery plus CRT (regional HR 0.15; metastatic HR 0.31) improved survival compared with no treatment (P < .02). Conclusion. In ACC, surgery is associated with improved survival, even in metastatic disease. Surgery should be considered for select patients as part of multimodality treatment. (Surgery 2014;156:1531-41.) 
WITH INCREASING USE OF ABDOMINAL CROSS-SECTIONAL IM-AGING, adrenal lesions are more commonly identified, occurring in up to 4-6% of the ambulatory population. 1, 2 In contrast, malignant adrenal tumors are extremely rare, with an incidence of approximately 1-2 cases per million. [1] [2] [3] Despite its rarity, the consequences of adrenal cancer are substantial. Almost all patients present with widely metastatic disease, and these patients die within months of diagnosis. [1] [2] [3] Malignancy in an adrenal nodule cannot be predicted unless it invades into nearby structures or has metastasized. 1, 2, 4 Percutaneous biopsy is not diagnostic except for confirming metastatic tumor of extra-adrenal origin. 5 Tumor size greater than 4-6 cm, heterogeneous patterns and irregular surfaces on imaging, and hormone hypersecretion all increase the likelihood of malignancy. Even after operative resection, malignant potential is difficult to determine histologically. It can be approximated using the Weiss criteria, but malignancy is only confirmed when the tumor recurs or metastasizes. 6, 7 Therefore, major diagnostic dilemmas arise in the evaluation of patients with solitary adrenal nodules. 5 Complete operative resection remains the only curative treatment for adrenocortical carcinoma (ACC), whereas adjuvant treatment with chemotherapy and/or radiation may have a modest improvement in survival. 8 The major predictor of long-term survival is presentation with either stage I or II disease and the ability to undergo complete resection of the tumor. 2, 9, 10 Five-year survival rates range from 16 to 34% overall and only 32-62% in patients who undergo ''curative resection.'' The survival is as low as 9% in the case of an incomplete resection. 1 The role of surgery for patients with advanced disease has not yet been elucidated.
It has been difficult to study the optimal treatment of ACC because of its rarity. Most peerreviewed guidelines focus on evaluation and removal of functioning, nonmetastatic adrenal tumors. Unfortunately, there is no standardized approach to treating malignant adrenal cancers, especially if they are metastatic at the time of diagnosis. The role of operative resection is controversial if the goal is not curative intent. If the perioperative risks are thought to be acceptable, it is reasonable to debulk a functional ACC for palliation. Small case series have also shown a possible survival benefit for operative resection in patients with locally recurrent or metastatic ACC 11, 12 ; however, there may be little benefit when complete resection of the primary and all metastases cannot be achieved; this must be weighed against the perioperative risks and delay in systemic treatment. 1 Given the lack of data on this rare but highly lethal cancer, we evaluated the outcomes of patients diagnosed with ACC using a large population-based cancer registry during a 10-year time span. Our aim was to determine how the following treatments are associated with stagespecific survival in ACC: surgery, chemotherapy, and/or radiation therapy.
METHODS
Patient sample. Newly diagnosed ACC cases were abstracted from the prospectively collected California Cancer Registry (CCR) for the years 1999-2008. Records were linked to inpatient and ambulatory hospital records maintained by the California Office of Statewide Health Planning and Development database via the use of unique patient identifiers, which allowed for longitudinal follow-up for each patient from the time of cancer diagnosis. This study was approved by the University of California, Los Angeles, and the CCR Institutional Review Boards.
Patients were identified by the SITE_02 variable in CCR, which codes for the location where the tumor originated. Patients were included if they had a SITE_02 variable that coded for adrenal tumor; International Classification of Disease (ICD)-0-3 codes C74.0, C74.1, and C74.9; as well as the following ICD-0-3 histology codes to ensure that only patients with ACC were captured: 8010 (carcinoma, not otherwise specified), 8020 (carcinoma, undifferentiated type), 8140 (adenocarcinoma, not otherwise specified), and 8370 (adrenal cortical carcinoma). We excluded patients with unknown race (n = 7) and those with unknown staging (n = 35). An additional 4 patients were diagnosed at death and also were excluded. Median follow-up time was 18.8 months, and 80 patients had at least 5 years of follow-up.
Variables. Demographics, clinical characteristics, treatment, and outcomes were analyzed collectively and by disease stage. Demographic data included age, sex, race/ethnicity, socioeconomic status (SES), and patient comorbidities. Race/ ethnicity was defined as non-Hispanic white, nonHispanic black, Hispanic, and Asian/Pacific Islander. SES score was coded as the quintiles of Yost's index of SES level based on a principal components analysis where the least SES score was 1 and the greatest SES score was 5. 13 Comorbidity was scored via use of the Charlson comorbidity scoring system, classified as 0 or >0.
14 Data regarding institution type were stratified into the following categories: private, public, academic, and health maintenance organization hospitals.
Clinical data included cancer size, stage, and whether the tumor was functional (associated with hormone hypersecretion). Cancer size was classified as <10 cm, 10-20 cm, 20-30 cm, and >30 cm. Stage was defined as local, regional (direct extension and/or positive lymph nodes), or metastatic via use of the CCR variable SUMSTAGE for stage at diagnosis. Treatments were defined as none (no treatment received), surgery alone, chemotherapy and/or radiation alone (CRT), and surgery combined with chemotherapy and/or radiation (S+CRT). The treatment variables were derived from the CCR variables surgdate (surgery), rxdatec (chemotherapy), and rxdater (radiation) as well as California Office of Statewide Health Planning and Development CPT variables for chemotherapy, radiation, and surgery (Supplementary Table I 
RESULTS
Between 1999 and 2008, 367 patients were identified with ACC in California who met inclusion criteria for the study (Table I) . Mean age at diagnosis was 53 years, and 57.8% were female. Most patients were healthy with relatively few comorbidities, with only 22.3% having a Charlson Index score of greater than 1. At presentation, the majority of patients had disease that had spread either regionally (17.4%, n = 64) or was metastatic (45.5%, n = 167) (Table II) . Median tumor size was 9 cm for local disease (range 0.3-34 cm), 12 cm for regional (range 2-28 cm) and 12 cm for metastatic disease (range 2-34 cm). The mean time from diagnosis to treatment was 18.9 days.
Only 18.0% (n = 66) were identified as being functional tumors, and the majority (77.3%, n = 51) were associated with Cushing's syndrome. Of patients with metastatic disease, 64.1% of those with functional tumors underwent surgery with or without CRT, 25.6% underwent CRT alone, and only 10.3% had no treatment. Patients with metastatic disease who had nonfunctional tumors were less likely to undergo surgery either with or without CRT (34.3%) and more likely to have either CRT alone (31.3%) or no treatment (34.4%) (P = .0011).
All-cause median survival was 1.7 years, with metastatic patients having worse survival (7.4 years for local disease, 2.6 years for regional, and 0.3 years for metastatic, P < .0001; Fig 1) . Oneyear survival was 91.8% for local, 73.4% for regional, and 23.7% for metastatic disease. Fiveyear survival was 61.7% for local, 39.1% for regional, and 6.7% for metastatic disease. There was no association between tumor size and 5-year survival for patients with local disease (69.7% for <10 cm, 62.9% for 10-20 cm, and 60.0% for >20 cm; P = .69).
Of 254 patients who underwent surgery, the 30-day postoperative mortality was 2.8% (n = 7). In addition to adrenalectomy, procedures involving partial or total resection of other organs performed at the time of original surgery included kidney (20.1%), spleen (8.3%), pancreas (5.1%), and liver (3.1%). Only 9.1% of patients were coded as having lymph node dissection. Only 4.7% (n = 12) of patients were coded as having a laparoscopic procedure as their initial operation. The majority of patients in the local (86.8%, n = 118) and regional (75.0%, n = 48) groups underwent surgery as the sole treatment (Table II) . In contrast, most patient with metastatic disease underwent CRT either alone (29.9%, n = 50) or in combination with surgery (26.3%, n = 44). Only a minority of patients with metastatic disease underwent surgery alone (15.0%, n = 25), and the remainder (28.7%, n = 48) did not undergo any treatment.
There were some disparities in receipt of care in univariate analysis of the entire patient cohort. There was a trend towards increased time from diagnosis to surgery for black patients (mean , whereas those who underwent the most aggressive treatment with S+CRT were younger (mean 42.2 years, P < .0001). There were no other differences in demographics between the treatment groups. For all patients, factors associated with decreased survival in univariate analysis included increased age (hazard ratio [HR] 1.20, P < .0001), low SES (HR 1.80, P = .001), and the presence of comorbidities (HR 1.65, P = .0001). A diagnosis of Cushing's syndrome was also a poor prognostic factor of survival (HR 1.49, P = .0181). Female sex was associated with improved survival (HR 0.65, P = .0008). Compared with private hospitals, treatment at either academic (HR 0.68, P = .0186) or health maintenance organization hospitals (HR 0.66, P = .0091) was associated with improved survival. Tumor size was not associated with outcomes.
Treatment type was an important predictor of survival in univariate analysis. For all patients, surgery with or without systemic treatment was a predictor of improved survival compared with no treatment (surgery: HR 0.13, P < .0001; S+CRT: HR 0.29, P < .0001). For patients with local disease, surgery was associated with improved survival over no treatment (HR 0.23, P = .0021). For patients with regional disease, both surgery (HR 0.20, P = .0002) and S+CRT (HR 0.19, P = .0057) were associated with improved survival over no treatment. Patients with metastatic disease had improved survival with surgery (HR 0.42, P = .0008), CRT (HR 0.56, P = .0058), and S+CRT (HR 0.24, P < .0001) over no treatment.
Survival analysis for all patients using the Kaplan-Meier method showed that surgery either alone or in combination with CRT was associated with improved survival (Fig 2, A) . Median survival for the local disease group was 8.6 years for those treated with surgery, 3.1 years for S+CRT, and 1.0 year for no treatment (P = .0003). Median survival for the regional disease group was 3.7 years for surgery, 4.7 years for S+CRT, 1.1 years for CRT, and 0.4 years for no treatment (P = .0003). Median survival for metastatic disease was 0.4 years for those treated with surgery, 0.3 years for CRT, 1.1 years for S+CRT, and 0.1 years for no treatment (P < .001) (Fig 2, B) .
In multivariable Cox regression analysis of all patients, after adjusting for a number of factors including age, gender, SES, comorbidities, and tumor size, we found that the strongest predictor of mortality was metastatic disease (HR 5.44 compared with local disease, P < .001) (Table III) . Increasing age (HR 1.17, P = .0008) and the presence of Cushing's syndrome (HR 1.66, P = .0081) also were associated with decreased survival. In the same regression analysis, surgery either alone (HR 0.40, P = .0003) or in combination with CRT (HR 0.39, P = .0002) was a predictor of survival over no treatment. CRT, Chemotherapy and/or radiation.
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In stage-specific multivariable regression analysis, for patients with regional disease (Table IV) , both surgery (HR 0.13, P < .001) and S+CRT (HR 0.15, P = .0079) were associated with improved survival over no treatment. For patients with metastatic disease, both surgery (HR 0.52, P < .02) and S+CRT (HR 0.31, P < .001) improved survival over no treatment, whereas CRT was associated with a trend (HR 0.65, P = .0928) towards improved survival (Table  IV) . For patients with metastatic disease, multimodality treatment (S+CRT) was associated with improved survival over CRT alone (HR 0.47, P = .0025) and a trend toward improved survival over surgery alone (HR 0.59, P = .08). Cushing's syndrome was associated with increased mortality for local (HR 4.16, P = .0045) and regional (HR 5.49, P < .001) disease, but was not a predictor for metastatic disease.
DISCUSSION
In this contemporary population-based cohort of patients with adrenocortical carcinoma, we have demonstrated that surgery either alone or in combination with CRT is associated with improved survival. When we accounted for a number of patient and tumor-related characteristics, surgery was predictive of improved survival for patients with regional and metastatic disease. For patients with metastatic disease, multimodality treatment with S+CRT was more effective than CRT alone. S+CRT may improve survival over surgery alone for metastatic patients, but we could not show a statistically significant relationship in our study likely because of low power. As shown by the low 30-day postoperative mortality in our patient cohort, surgery for ACC can be performed safely for appropriately selected patients.
Previous studies using the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) staging system have reported 5-year survival of 62% for local (stage I/II) disease and 7% for patients with stage IV disease. 15 A recent study using the SEER database reported that patients with regional disease (stage III or IV) had mean survival of 73 months if treated with surgery compared with 35 months if not treated with surgery (P = .007). 16 They found that operative resection was associated with a decrease in mortality in multivariate analysis (HR 10.46, P < .001); however, they did not analyze the impact of nonoperative treatment on survival and excluded patients with metastatic disease. To expand on the current literature, our study analyzed the impact of both surgery and systemic therapy on survival. We specifically included metastatic patients, a particularly challenging population.
Because most patients present with advanced disease, there has been considerable interest in adjuvant treatment. Mitotane is the only systemic therapy approved for ACC. It typically is used as an adjuvant treatment after resection for high-risk patients, where it has shown some efficacy in prolonging recurrence-free survival. 17 It also is used often for patients who are not resectable (as the result of local invasion or metastasis) or have recurrent disease, although recent studies have shown a response rate of only 30% in this setting, with even rarer patients achieving complete tumor regression. 8 Mitotane inhibits steroid synthesis and induces hepatic clearance of cortisol, and it can improve symptoms related to Cushing's syndrome. Although there are conflicting data on the efficacy of mitotane, it remains the systemic treatment of choice largely because of the lack of other well-established therapies.
The authors of a recent randomized trial compared multidrug chemotherapy regimens (etoposide, doxorubicin, and cisplatin [EDP] plus mitotane vs streptozocin plus mitotane) for patients with advanced ACC who were deemed to be unresectable. 18 Patients in the EDP group had a longer progression-free interval, but overall survival was not significantly different between the groups and was still poor (14.8 months vs 12.0 months, P = .07). Radiation also can be considered for high-risk patients after operative resection or for palliation of metastatic disease not amenable to surgery (eg, bone and brain). Tumor response rates have been reported of up to 40%, but there has been no proven survival benefit with radiation.
Given the lack of effective systemic therapy, surgical resection has been the mainstay of treatment for ACC. Complete operative resection with microscopically negative margins and leaving the tumor capsule intact to avoid tumor spillage gives the best chance for a long-term cure. 9 Extensive lymphadenectomy and en-bloc resection of adjacent structures should be performed as necessary to achieve complete resection, providing they can be done safely. 19 Surgical debulking for symptoms related to hormone hypersecretion can provide significant palliation and improve the efficacy of additional adjuvant treatment. 20 Studies have also supported repeat surgery for local recurrence, with increased overall 5-year survival and decreased pain and symptoms associated with hormone hypersecretion compared with patients who underwent adjuvant systemic therapy or no treatment. 21 In our opinion, because of the lack of efficacy data and potential side effects of chemoradiation, we cannot say whether it currently has a role in patients with local disease who have undergone complete resection, especially in those without high-risk features (eg, high grade, rapid tumor growth, or intraoperative violation of tumor capsule). Patients with presumed local disease who undergo incomplete resection because of intraoperative findings of local invasion or metastasis should have adjuvant treatment with mitotane or a multidrug chemotherapy regimen if they are able to tolerate it. Those patients who are known to be unresectable preoperatively should be offered neoadjuvant treatment to evaluate primary and distant tumor response. Neoadjuvant treatment allows for observation of tumor biology and response to treatment before offering an extensive surgery that can have great morbidity. The rate of tumor growth, which is not known in this dataset, may reflect how aggressively an individual tumor will behave. This can be a useful prognostic marker that can help to guide treatment. In patients with nonlocalized disease, surgery should be offered as initial treatment on a case-by-case basis for patients with: (1) ability to resect the primary and any gross metastasis, (2) low burden of disease, and/or (3) lack of significant comorbid conditions. In general, for those that present with metastatic disease, we believe noncurative debulking should be considered for patients with a readily resectable primary lesion and low burden of metastatic disease, or for palliation of symptoms related to hormone hypersecretion. Patient selection is critical to ensure that surgery is offered to those who are most likely to benefit either through prolonged survival or improved quality of life. As reflected in the low postoperative mortality and apparent benefit of surgical resection in our study, patients may have been appropriately selected based on their burden of disease and ability to tolerate an extensive surgery. The role of adjuvant treatment may evolve as new and potentially more effective chemotherapy becomes available.
As expected, tumors associated with Cushing's syndrome were associated with a worse prognosis for local and regional disease. The negative prognostic implication of Cushing's syndrome in ACC has previously been reported. 22 The etiology is not completely clear but it may be related to either tumor biology or a direct impact of cortisol production on tumor cell growth and host defenses. 22 The low prevalence of hormone hypersecretion (18.0%) associated with ACC is likely underestimated in our study due to reliance on ICD-9 coding. Most studies report that approximately 60% of patients with ACC have associated hormone hypersecretion, most commonly Cushing's syndrome with or without virilization. 23 The patients that were coded as having a hormonally active tumor were likely the most advanced cases, and would be expected to have worse survival. Despite being undercoded, we included the variable in the analysis because we thought that it was clinically significant and informative to the reader in confirming the negative prognostic relationship between Cushing's syndrome and survival in ACC. We performed the same analysis excluding Cushing's syndrome, and there was no difference in the results.
This study has several limitations. Observational data cannot capture potential sources of bias arising from patient selection factors. There may be a physician referral bias, and some patients may have refused surgery. The extent of disease burden, tumor grade, completeness of resection, and specific chemotherapy and/or radiation regimen are not available in this database. Follow-up for treatments received outside of California was not captured in this data. because of the small number of patients with local disease treated with CRT either alone (n = 0) or in combination with surgery (n = 11), we were not able to separately analyze the effect of adjuvant treatment in this subgroup.
Because of the difficulty in defining malignancy in local ACC, patients with benign tumors may have been misdiagnosed as malignant. However, the large median tumor size, confirmation by histology, and use of open rather than laparoscopic surgery all suggest that these tumors were malignant. In addition, our patient cohort mimics the SEER database, which reported that 40.6% of patients present with local disease, 17.9% with regional, and 34.8% with metastatic disease. 24 Despite these limitations, our study strengths include a relatively large sample size of this rare cancer from a comprehensive statewide database with longitudinal follow-up, which is representative of real world clinical practice.
In conclusion, in ACC, surgery may be associated with improved survival for patients with regional and metastatic disease. Patients with metastatic disease likely benefit most from multimodality treatment (surgical resection plus adjuvant chemotherapy and/or radiation). These findings suggest that surgery should be considered for appropriately selected patients. Dr Michael W. Yeh: I agree that selection bias is a serious problem in this retrospective study. Given the small numbers, it's hard to adjust for nonrandom treatment assignment with something like an instrumental variable or propensity scoring, for example, since modeling attempts will just break down.
The conclusion that we cannot avoid, I think, is that surgery is at least not harmful for patients with distant disease. I say that because distant disease is unambiguously coded. Yes, there are likely select patients with less-extensive disease who are undergoing surgery, but surgery doesn't seem to worsen survival. If anything, there was a slight improvement. And yes, this is just an association.
I think the conclusions we can draw are fairly limited, mainly that we shouldn't be nihilistic about this disease. Just because a patient has a small amount of disease in the chest doesn't mean we should just not operate and give up. That's really the only message I have.
Dr Haggi Mazeh (Jerusalem, Israel): No disclosures. In continuation to what Dr Doherty was asking, we know that patients who underwent surgery did better. But is this the chicken or the egg? Maybe because they had one metastasis, a single one, isolated, that's why they had underwent surgery, and that's why they did better. So you really didn't prove that surgery actually made them better.
I'm wondering if you looked at, within the patients that had surgery, what kind of metastatic disease did they have? Extensive? What were the considerations for surgery? Could you elaborate on that from the data that you got?
Dr Michael W. Yeh: The question is what was what was the extent of disease? First of all, I agree that there is significant selection bias. Maybe it is indeed just as you say, that the patients with low-volume distant disease are exactly the ones being selected for surgery and so they have better survival, in which case surgery is just an indicator. I agree that that's a significant limitation of this study.
In terms of do we know how bad the distant disease was or the volume? We are unable to discern that from the database.
Dr John Hanks (Charlottesville, VA): But, again, with the metastatic and the regional disease, you still show a fairly grim survival statistic, so I think that future studies need to look into the question I am going to ask: At what cost? Do we have any data on quality of life?
We can do these surgeries with a bump up in survival, but do we have a way of assessing the quality of life of the patients and/or the cost to them or their health care providers in giving us this small advance in survival?
Dr Michael W. Yeh: I don't have the data to answer your question, but I agree that achieving a small incremental increase in survival should not be our aim at any cost. I agree that quality of life should be considered.
Dr Michael J. Demeure (Scottsdale, AZ): No disclosures. I realize the limitations you have, but maybe you can look at the data or shed some light on some things maybe you can tell us. The people who had resection of metastatic disease, were they all at the initial operation or were they resection of metastasis? Or were these only patients at time of presentation?
Was the likelihood of having a resection of metastatic disease more likely if the patient was treated in an academic center, as opposed to a private center? So maybe the willingness to be aggressive might vary by where the patient was treated.
Finally, were you more likely to resect metastatic disease if the tumor was hormonally active because maybe the benefit isn't so much the patient is living because the tumor is knocked back, but maybe the morbidity of excess cortisol that might be knocked back a little bit by resecting metastatic disease. So maybe you can shed some light on some things that I think you can answer from your data that you didn't address.
Dr Michael W. Yeh: I'm going to take these questions back and we'll address them in the revision. Dr Demeure is talking about multiple operations, if I understand correctly. Most of these patients only had a single surgery. But reoperations are something we can track, and we will try to address this question of multiple procedures and multiple resections in the next version of the manuscript.
Dr Michael J. Demeure (Scottsdale, AZ): The likelihood of surgery if they're at an academic center?
Dr Michael W. Yeh: Yes, being treated at an academic center appeared to be protective, and we will also look into that question.
Dr Barb Miller (Ann Arbor, MI): No disclosures. I think to use a generic state database or a national database for this type of disease is a poor use and really can't be used at all, because you really need to drill down to patient-specific characteristics in terms of making decisions about how to treat patients. It's so rare, it's so difficult that I think most of these large databases reflect the overall care that people get. I think we know that in general it's quite poor.
That's also borne out in some of the German data, where they reported that basically the evaluation of patients---you said that only 20% had hypersecretion---we know that basically, from their papers, that only 20% of the patients got any sort of preoperative hormonal evaluation, that 60% of those didn't have a complete hormonal evaluation, that they are not getting preoperative imaging. You can't even stage patients appropriately ahead of time.
And the follow-up is poor. That doesn't even include the type of surgery. So I think large databases for this at a state and national level will not reflect what's truly happening in the patients to make treatment decisions.
